Agenus
Update in progressAGEN (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Agenus Inc. is a clinical‑stage biotechnology company developing immunotherapies for cancer and infectious diseases in the United States and worldwide. It offers Retrocyte Display, an antibody discovery platform, and related display technologies. Its programs include Balstilimab (PD-1), AGEN1181 (CTLA-4), AGEN2373 (CD137), AGEN1423 (CD73/TGF-β TRAP), AGEN1571 (ILT2), BMS-986442 (TIGIT), and others such as INCAGN1876, INCAGN2390, INCAGN2385, MK‑4830, and AGEN1884. It collaborates with multiple partners.
Company score
- Sentiment
- 0.38
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.17
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.22
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Loading section